Outcomes of patients with sepsis due extensively drug-resistant bacterial infections with and without polyspecific intravenous immunoglobulin therapy: A retrospective study

Sepsis caused by extensively drug-resistant (XDR) pathogens is characterized by high mortality rates. Polyspecific intravenous immunoglobulin (IVIG) has been used as an adjunctive therapy in sepsis for a long time, but it is not routinely recommended due inconclusive results. This retrospective study investigates the effect of IVIG therapy on 30-day mortality in 50 patients with sepsis caused by XDR pathogens, according to Sepsis-3 criteria. Fifty patients were included, with 28 receiving IVIG alongside standard treatment. Mortality was 74%, with no significant difference in 30-day mortality (71.4% for IVIG-treated vs 77.3% for non-IVIG-treated, P = .886) or intensive care unit (ICU) stay duration (median of 9.0 days for both groups, P = .883) between the groups. The study concludes that adding polyspecific IVIG to conventional sepsis treatment does not reduce 30-day mortality or ICU stay in XDR pathogen-induced sepsis.